Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
Authors
Keywords
-
Journal
OncoImmunology
Volume -, Issue -, Pages 00-00
Publisher
Informa UK Limited
Online
2018-06-27
DOI
10.1080/2162402x.2018.1466018
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells
- (2017) David H. Raulet et al. IMMUNOLOGICAL REVIEWS
- CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
- (2017) Julia A. Wagner, Maximillian Rosario, Rizwan Romee, Melissa M. Berrien-Elliott, Stephanie E. Schneider, Jeffrey W. Leong, Ryan P. Sullivan, Brea A. Jewell, Michelle Becker-Hapak, Timothy Schappe, Sara Abdel-Latif, Aaron R. Ireland, Devika Jaishankar, Justin A. King, Ravi Vij, Dennis Clement, Jodie Goodridge, Karl-Johan Malmberg, Hing C. Wong, Todd A. Fehniger JOURNAL OF CLINICAL INVESTIGATION
- LFA-1 Activation in NK Cells and Their Subsets: Influence of Receptors, Maturation, and Cytokine Stimulation
- (2017) Doris Urlaub et al. JOURNAL OF IMMUNOLOGY
- Identification of essential genes for cancer immunotherapy
- (2017) Shashank J. Patel et al. NATURE
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
- (2017) Caroline Jochems et al. Oncotarget
- Cd226−/− natural killer cells fail to establish stable contacts with cancer cells and show impaired control of tumor metastasis in vivo
- (2017) Ji Sung Kim et al. OncoImmunology
- Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors
- (2017) Sheila López-Cobo et al. OncoImmunology
- Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis
- (2017) Simin Kiany et al. OncoImmunology
- Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
- (2017) Renee N. Donahue et al. Journal for ImmunoTherapy of Cancer
- The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3
- (2017) Lulu Ni et al. Scientific Reports
- Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma
- (2017) Cathrin Ritter et al. Scientific Reports
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Targeting natural killer cells in cancer immunotherapy
- (2016) Camille Guillerey et al. NATURE IMMUNOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
- (2016) Rika Fujii et al. Oncotarget
- IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
- (2016) Peter S. Kim et al. Oncotarget
- Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells
- (2016) Sofia R. Gameiro et al. Oncotarget
- Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response inKRASwild-type metastatic colorectal cancer patients
- (2016) Cristiana Lo Nigro World Journal of Gastrointestinal Oncology
- Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis
- (2015) J Wild et al. LEUKEMIA
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
- (2015) A M Martin et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Epigenetic therapy for solid tumors: from bench science to clinical trials
- (2015) Yen-Yi Juo et al. Epigenomics
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer
- (2015) Christopher R. Heery et al. JAMA Oncology
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
- (2013) Eric O. Long et al. Annual Review of Immunology
- Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor
- (2013) Marian Iwamoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors
- (2013) Madeleine SQ Kortenhorst et al. Epigenetics
- The future of epigenetic therapy in solid tumours—lessons from the past
- (2013) Nilofer Azad et al. Nature Reviews Clinical Oncology
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells
- (2013) Shiguo Zhu et al. PHARMACEUTICAL RESEARCH
- Activating natural cytotoxicity receptors of natural killer cells in cancer and infection
- (2013) Joachim Koch et al. TRENDS IN IMMUNOLOGY
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
- (2012) Alison C. West et al. OncoImmunology
- Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
- (2011) R Pili et al. BRITISH JOURNAL OF CANCER
- Entinostat for treatment of solid tumors and hematologic malignancies
- (2011) Jeffrey Knipstein et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
- (2011) K Ted Thurn et al. Future Oncology
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
- (2011) Emilie Mamessier et al. JOURNAL OF CLINICAL INVESTIGATION
- Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
- (2010) Teemu T. Junttila et al. CANCER RESEARCH
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Histone deacetylases and the immunological network: implications in cancer and inflammation
- (2009) A Villagra et al. ONCOGENE
- Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells
- (2008) Mareike Schmudde et al. CANCER LETTERS
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started